Pharmaceutical - Cardio-vascular, Genzyme

Filter

Current filters:

Cardio-vascularGenzyme

Popular Filters

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder

30-01-2013

The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro

19-10-2012

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory yesterday voted by…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA

31-05-2012

The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen…

BiotechnologyCardio-vascularFinancialGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRegulationSanofi

Genzyme and Isis file Kynamro NDA in USA

02-04-2012

Biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN), has submitted a New Drug…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Isis sees Kynamro delay; adds new drugs to pipeline

15-12-2011

California, USA-based Isis Pharmaceuticals (Nasdaq: ISIS) announced yesterday that there will be a slight…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamromipomersenNephrology and HepatologyPharmaceuticalRegulationResearchSanofi

Back to top